Protagonist Therapeutics (PTGX) Announces Preliminary Phase 1 Study Results with PTG-300 | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.
MENU

Protagonist Therapeutics (PTGX) Announces Preliminary Phase 1 Study Results with PTG-300

Protagonist Therapeutics (PTGX) Announces Preliminary Phase 1 Study Results with PTG-300
Peptide News from Biotech and Pharma, Raw News September 20, 2017

PTG-300 is an injectable hepcidin mimetic peptide, discovered using the company's proprietary technology platform. Protagonist is developing ...

Email

support@boulderpeptide.org

s2Member®
loading...